96 results
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
7 Feb 24
23andMe Reports Third Quarter Fiscal 2024 Financial Results
4:03pm
, litigation settlements, gains or losses on dispositions of subsidiaries, transaction-related costs, and cyber security incident expenses, net of probable … assets
Stock-based compensation expense
Loss on disposition of Lemonaid Health Limited and transaction-related costs
Litigation settlement cost
Goodwill
8-K/A
ME
23andMe Holding Co - Ordinary Shares
1 Dec 23
Regulation FD Disclosure
4:06pm
of the costs and related impacts of this incident and related litigation, including, without limitation, the availability of insurance to offset some … Statements
This Amendment contains “forward-looking” statements, which are subject to the safe harbor provisions of the Private Securities Litigation
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
8 Nov 23
23andMe Reports Second Quarter Fiscal 2024 Financial Results
4:29pm
or not representative of underlying trends of our business, including but not limited to: changes in fair value of warrant liabilities, litigation … on disposition of Lemonaid Health Limited and transaction-related costs
Litigation settlement cost
Total Adjusted EBITDA
(1)There was no Therapeutics revenue
8-K
ca86oz8bjsxb2wlq66n6
10 Oct 23
Regulation FD Disclosure
4:17pm
S-8
EX-99.1
re9npks50rdwm
15 Sep 23
Registration of securities for employees
4:06pm
8-K
EX-99.1
q9vz 9hdv10ncrf
8 Aug 23
23andMe Reports FY2024 First Quarter Financial Results
4:10pm
DEFR14A
6t1ss12bv j2x2ut
4 Aug 23
Revised proxy
4:05pm
DEFR14A
c61ts9hzn
26 Jul 23
Revised proxy
9:14pm
8-K
EX-99.1
2eee6
25 May 23
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
4:08pm
8-K
EX-10.1
4zpuzrpc
9 Dec 22
Departure of Directors or Certain Officers
8:05am
8-K
EX-99.1
vzk67j ig
9 Nov 22
Investor Presentation November 2022
7:30am
424B3
9tzwokz9eqd6g 8g8sng
7 Nov 22
Prospectus supplement
4:33pm